Bashir B, Iqbal Z, Adam S, et al. Microvascular complications of diabetes and obesity – role of bariatric surgery. Obes Rev 2023; 24(10) :e13602. Epub ahead of print. https://doi.org/10.1111/obr.13602

Callaghan BC, Gao L, Li Y, et al. Diabetes and obesity are the main metabolic drivers of peripheral neuropathy. Ann Clinical Translational Neurology 2018;5(4): 397-405. https://doi.org/10.1002/acn3.531

Callaghan BC, Xia R, Reynolds E, et al. Association between metabolic syndrome components and polyneuropathy in an obese population. JAMA Neurol 2016;73(12):1468-76. https://doi.org/10.1001/jamaneurol.2016.3745

Hanewinckel R, Drenthen J, Ligthart S, etal. Metabolic syndrome is related to polyneuropathy and impaired peripheral nerve function: a prospective population-based cohort study. J Neurol Neurosurg Psychiatry 2016;87(12):1336–42. https://doi.org/10.1136/jnnp-2016-314171

Azmi S, Ferdousi M, Liu Y, et al. Bariatric surgery leads to an improvement in small nerve fibre damage in subjects with obesity. Int Journal Obesity Lond 2021;45(3):631-8.

Zhang L, Krzentowski G, Albert A, et al. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 2001;24(7):1275-9. https://doi.org/10.2337/diacare.24.7.1275

Henricsson M, Nyström L, Blohmé G, et al. The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden. Diabetes Care 2003;26(2):349-54. https://doi.org/10.2337/diacare.26.2.349

Chao JR, Lai MY, Azen SP, et al. Retinopathy in persons without diabetes: the Los Angeles Latino Eye Study. Invest Ophthalmol Vis Sci 2007;48(9):4019-25. https://doi.org/10.1167/iovs.07-0206

Gray N, Picone G, Sloan F, et al. The relationship between BMI and onset of diabetes mellitus and its complications. SouthMedJ 2015; 108(1):29-36.

van Leiden HA, Dekker JM, Moll AC, etal. Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn Study. Diabetes Care 2002;25(8):1320-5. https://doi.org/10.2337/diacare.25.8.1320

Dirani M, Xie J, Fenwick E, etal. Are obesity and anthropometry risk factors for diabetic retinopathy? The Diabetes Management Project. Invest Ophthalmol Vis Sci 2011;52(7):4416-21. https://doi.org/10.1167/iovs.11-7208

Ejerblad E, Fored CM, Lindblad P, etal. Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006;17(6):1695-702. https://doi.org/10.1681/ASN.2005060638

Peters AM, Ciapryna MB, Bowles PF, et al. Obesity does not accelerate the decline in glomerular filtration rate associated with advancing age. Int J Obesity (Lond) 2009;33(3):379–81. https://doi.org/10.1038/ijo.2009.6

Iseki K, Ikemiya Y, Kinjo K, et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Internat 2004;65(5):1870–6. https://doi.org/10.1111/j.1523-1755.2004.00582.x

Gelber RP, Kurth T, Kausz AT, et al. Association between body mass index and CKD in apparently healthy men. Am Journal Kidney Diseases 2005;46(5):871–80. https://doi.org/10.1053/j.ajkd.2005.08.015

Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA 2005;293(4):455–62. https://doi.org/10.1001/jama.293.4.455

Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncology 2005l;23(21):4742–54. https://doi.org/10.1200/JCO.2005.11.726

van Dijk BA, Schouten LJ, Kiemeney LA, et al. Relation of height, body mass, energy intake, and physical activity to risk of renal cell carcinoma: results from the Netherlands Cohort Study. Am J Epidemiol 2004; 160(12): 1159-67. https://doi.org/10.1093/aje/kwh344

Vivante A, Golan E, Tzur D, et al. Body mass index in 1.2 million adolescents and risk for end-stage renal disease. Arch Int Med 2012; 172(21):1644–50. https://doi.org/10.1001/2013.jamainternmed.85

Hsu CY, Iribarren C, McCulloch CE, et al. Risk factors for end-stage renal disease: 25-year follow-up. Arch Int Med 2009;169(4):342–50. https://doi.org/10.1001/archinternmed.2008.605

Munkhaugen J, Lydersen S, Widerøe TE, et al. Prehypertension, obesity, and risk of kidney disease: 20-year follow-up of the HUNT I study in Norway. Am J Kidney Dis 2009;54(4):638–46. https://doi.org/10.1053/j.ajkd.2009.03.023

Chandie Shaw PK, Berger SP, Mallat M, etal. Central obesity is an independent risk factor for albuminuria in nondiabetic South Asian subjects. Diabetes Care 2007;30(7):1840–4. https://doi.org/10.2337/dc07-0028

Kramer H, Luke A, Bidani A, et al. Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. Am J Kidney Diseases 2005;46(4):587-94. https://doi.org/10.1053/j.ajkd.2005.06.007

Polemiti E, Baudry J, Kuxhaus O, et al. BMI and BMI change following incident type 2 diabetes and risk of microvascular and macrovascular complications: the EPIC-Potsdam study. Diabetology 2021;64(4):814-

https://doi.org/10.1007/s00125-020-05362-7

Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380(24): 2295-2306. https://doi.org/10.1056/NEJMoa1811744

Heerspink HJL, Stefánsson BV, Correa-Rotter R, etal. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383(15): 1436-46. https://doi.org/10.1056/NEJMoa2024816

Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2016; 374(11):1094. https://doi.org/10.1056/NEJMc1600827

Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377(7):644-57. https://doi.org/10.1056/NEJMoa1611925

Wiviott SD, Raz I, Bonaca MP, etal. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380(4):347-57. https://doi.org/10.1056/NEJMoa1812389

Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375(19):1834-44. https://doi.org/10.1056/NEJMoa1607141

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375(4):311-22. https://doi.org/10.1056/NEJMoa1603827

Bosch C, Carriazo S, Soler MJ, et al. Tirzepatide and prevention of chronic kidney disease. Clin Kidney J 2022;16(5):797–808. https://doi.org/10.1093/ckj/sfac274

Coleman KJ, Haneuse S, Johnson E, etal. Long-term microvascular disease outcomes in patients with type 2 diabetes after bariatric surgery: evidence for the legacy effect of surgery. Diabetes Care 2016;39(8):1400-07. https://doi.org/10.2337/dc16-0194

O'Brien R, Johnson E, Haneuse S, et al. Microvascular outcomes in patients with diabetes after bariatric surgery versus usual care: a matched cohort study. Ann Intern Med 2018;169(5):300-10.

Carlsson LM, Romeo S, Jacobson P, et al. The incidence of albuminuria after bariatric surgery and usual care in Swedish Obese Subjects (SOS): a prospective controlled intervention trial. Int J Obes 2015;39(1):169–75. https://doi.org/10.1038/ijo.2014.72

Miras AD, Chuah LL, Khalil N, et al. Type 2 diabetes mellitus and microvascular complications 1 year after Roux-en-Y gastric bypass: a case-control study. Diabetologia 2015;58(7):1443-7. https://doi.org/10.1007/s00125-015-3595-7

Adam S, Azmi S, Ho JH, etal. Improvements in diabetic neuropathy and nephropathy after bariatric surgery: a prospective cohort study. Obesity Surgery 2021;31(2):554-63. https://doi.org/10.1007/s11695-020-05052-8

Reynolds EL, Watanabe M, Banerjee M, etal. The effect of surgical weight loss on diabetes complications in individuals with class II/III obesity. Diabetologia 2023;66(7):1192-1207. https://doi.org/10.1007/s00125-023-05899-3

Merlotti C, Ceriani V, Morabito A, etal. Bariatric surgery and diabetic retinopathy: a systematic review and meta-analysis of controlled clinical studies. Obes Rev 2017;18(3):309–16. https://doi.org/10.1111/obr.12490

Adam S, Ho JH, Syed AA, et al. Response to letter to the Editor concerning: Adam S et al. Improvements in diabetic neuropathy and nephropathy after bariatric surgery: a prospective cohort study. Obesity Surgery 2022;32(10):3460-2.

Docherty NG, le Roux CW. Bariatric surgery for the treatment of chronic kidney disease in obesity and type 2 diabetes mellitus. Nature reviews Nephrology 2020;16(12):709-20. https://doi.org/10.1038/s41581-020-0323-4

Li K, Zou J, Ye Z, etal. Effects of bariatric surgery on renal function in obese patients: a systematic review and meta analysis. PLoSOne 2016;11(10):e0163907 https://doi.org/10.1371/journal.pone.0163907

Scheurlen KM, Probst P, Kopf S, et al. Metabolic surgery improves renal injury independent of weight loss: a meta-analysis. Surgery Obesity Related Dis 2019;15(6):1006-20. https://doi.org/10.1016/j.soard.2019.03.013

Friedman AN, Wahed AS, Wang J, et al. Effect of bariatric surgery on CKD risk. J Am Soc Nephrol 2018;29(4):1289-300.